The Food and Drug Administration has approved daraxonrasib, an oral tablet branded as Rasonque, for adults with metastatic pancreatic adenocarcinoma, providing a groundbreaking treatment that reduced the risk of death by 60% in phase 3 trials, according to Revolution Medicines and BioPharma Dive. Patients receiving the medication lived 13.2 months, compared to 6.7 months for those on chemotherapy. The agency cleared the drug just 35 days after accepting the application.
Pricing and Financial Access for Rasonque
Revolution Medicines set the wholesale acquisition cost for Rasonque at approximately $39,800 for a 30-day supply, pushing the annual list price to roughly $477,000, according to an SEC filing cited by BioPharma Dive. That figure sits more than double the list price of Merck’s Keytruda, the top-selling cancer medication. However, actual costs depend on insurance coverage. CFO Jack Anders noted on an investor call that Medicare Part D coverage and government discounts will likely lower the price by 20% to 30%, while the company’s (ON)Path program offers co-pays as low as $0 for eligible commercially insured patients. Evercore ISI analysts project the drug could reach $2.4 billion in sales next year.
Clinical Impact and Market Outlook
Daraxonrasib is not a cure, but it targets a target at one time considered undruggable and offers a life-extending option for patients who have undergone chemotherapy with limited success. The FDA label includes an “or” that allows doctors flexibility to use the drug as a first-line treatment or after one systemic therapy, according to RBC Capital Markets analyst Leonid Timashev.
Navigating Insurance and Out-of-Pocket Costs
Patients face complex insurance landscapes when seeking coverage for high-cost cancer medications. Many carriers require prior authorization before approving treatment. For Medicare plans with a deductible, out-of-pocket expenses can reach up to $615 before coinsurance costs of 25% begin. Once out-of-pocket spending on covered drugs hits $2,100, patients enter catastrophic coverage where plans cover 100% of costs for the remainder of the year. Medicaid may cover treatments and lab tests for eligible low-income households. CancerCare, a nonprofit advocacy organization, recommends that families review policy terms, keep centralized medical and financial records, maintain an expense log, and explore veterans’ benefits or community social work services.
Did you know?
The American Cancer Society estimates that roughly 67,000 people will be diagnosed with pancreatic cancer in 2026, making it the third-leading cause of cancer death behind lung and colorectal cancers.
Frequently Asked Questions
What is Rasonque approved to treat?
Rasonque is approved for adults with metastatic pancreatic adenocarcinoma, according to the FDA.
How much does Rasonque cost?
The list price is approximately $39,800 for a 30-day supply, or about $477,000 annually, though insurance, Medicare adjustments, and company assistance programs can significantly reduce out-of-pocket expenses for eligible patients, according to Revolution Medicines.
What are the common side effects of daraxonrasib?
What are your thoughts on this new FDA approval? Share your perspective in the comments below, or subscribe to our newsletter for more updates on oncology breakthroughs.
Related reading